Digital Microfluidics in Newborn Screening for Mucopolysaccharidoses: A Progress Report

Abstract

by Jon Washburn andDavid S. Millington
Int. J. Neonatal Screen. 2020, 6(4), 78; https://doi.org/10.3390/ijns6040078 - 15 FEB 2022
Cited by 9 | Viewed by 3060
Abstract
Newborn screening (NBS) for mucopolysaccharidosis type I (MPS I, Hurler syndrome) is currently conducted in about two-fifths of the NBS programs in the United States and in a few other countries. Screening is performed by measurement of residual activity of the enzyme alpha-l-iduronidase in dried blood spots using either tandem mass spectrometry or digital microfluidic fluorometry (DMF). In this article, we focus on the development and practical experience of using DMF to screen for MPS I in the USA. By means of their responses to a questionnaire, we determined for each responding program that is screening for MPS I using DMF the screen positive rate, follow-up methods, and classification of confirmed cases as either severe or attenuated. Overall, the results show that at the time of reporting, over 1.3 million newborns in the US were screened for MPS I using DMF, 2094 (0.173%) of whom were screen positive. Of these, severe MPS I was confirmed in five cases, attenuated MPS I was confirmed in two cases, and undetermined phenotype was reported in one case. We conclude that DMF is an effective and economical method to screen for MPS I and recommend second-tier testing owing to high screen positive rates. Preliminary results of NBS for MPS II and MPS III using DMF are discussed. Full article
(This article belongs to the Special Issue Neonatal Screening for Mucopolysaccharidoses)
12 pages, 540 KiB
Open AccessReview